Price Action to Note: Is Selling Ocera Therapeutics Inc Here a Winning Strategy?

Price Action to Note: Is Selling Ocera Therapeutics Inc Here a Winning Strategy?

The stock of Ocera Therapeutics Inc (NASDAQ:OCRX) is a huge mover today! About 162,078 shares traded hands. Ocera Therapeutics Inc (NASDAQ:OCRX) has declined 27.62% since March 11, 2016 and is downtrending. It has underperformed by 33.08% the S&P500.
The move comes after 6 months negative chart setup for the $52.74 million company. It was reported on Oct, 14 by Barchart.com. We have $2.26 PT which if reached, will make NASDAQ:OCRX worth $6.33 million less.

Analysts await Ocera Therapeutics Inc (NASDAQ:OCRX) to report earnings on November, 2. They expect $-0.36 earnings per share, down 5.88% or $0.02 from last year’s $-0.34 per share. After $-0.33 actual earnings per share reported by Ocera Therapeutics Inc for the previous quarter, Wall Street now forecasts 9.09% negative EPS growth.

According to Zacks Investment Research, “Ocera Therapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of proprietary compounds to treat acute and chronic orphan liver diseases. Ocera Therapeutics, Inc., formerly known as Tranzyme, Inc., is based in San Diego, California.”

Insitutional Activity: The institutional sentiment decreased to 0.62 in 2016 Q2. Its down 0.15, from 0.77 in 2016Q1. The ratio is negative, as 3 funds sold all Ocera Therapeutics Inc shares owned while 10 reduced positions. 2 funds bought stakes while 6 increased positions. They now own 6.77 million shares or 0.29% less from 6.79 million shares in 2016Q1.
Sabby Management Limited Liability Co holds 0.04% or 424,035 shares in its portfolio. Blackrock Fund Advsrs accumulated 0% or 46,236 shares. Manufacturers Life Insur The holds 0% of its portfolio in Ocera Therapeutics Inc (NASDAQ:OCRX) for 1,755 shares. Moreover, Renaissance Tech Limited Company has 0% invested in Ocera Therapeutics Inc (NASDAQ:OCRX) for 169,100 shares. California Public Employees Retirement accumulated 0% or 30,711 shares. Vhcp Mngmt Ltd Liability Co holds 1.57% or 796,550 shares in its portfolio. Blackrock Mgmt Limited Co last reported 0% of its portfolio in the stock. Morgan Stanley owns 1,317 shares or 0% of their US portfolio. Vanguard Group last reported 0% of its portfolio in the stock. Millennium Lc owns 516,343 shares or 0% of their US portfolio. The Pennsylvania-based Turner Ltd Partnership has invested 0.08% in Ocera Therapeutics Inc (NASDAQ:OCRX). Bridgeway Capital Mgmt Inc accumulated 0.01% or 210,860 shares. Tower Research Limited Liability (Trc) reported 343 shares or 0% of all its holdings. Moreover, Great Point Prtnrs has 1.07% invested in Ocera Therapeutics Inc (NASDAQ:OCRX) for 1.96 million shares. Geode Cap Mngmt Ltd Liability Com last reported 0% of its portfolio in the stock.

Another recent and important Ocera Therapeutics Inc (NASDAQ:OCRX) news was published by Seekingalpha.com which published an article titled: “Ocera Therapeutics: A Speculative Investment” on April 19, 2016.

OCRX Company Profile

Ocera Therapeutics, Inc., incorporated on January 12, 1998, is a clinical-stage biopharmaceutical company. The Firm is focused on acute and chronic orphan liver diseases. The Firm is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger. The Firm relies on third-party manufacturers to produce bulk drug substance and drug products required for commercial use and for its clinical trials.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment